Abbott Laboratories $ABT Stake Increased by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 9.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 157,256 shares of the healthcare product maker’s stock after acquiring an additional 14,112 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Abbott Laboratories were worth $21,057,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of ABT. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the third quarter worth about $31,000. Anfield Capital Management LLC increased its holdings in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after buying an additional 104 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in Abbott Laboratories during the second quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories during the 3rd quarter worth approximately $33,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.1%

Shares of NYSE ABT opened at $107.99 on Monday. Abbott Laboratories has a 12-month low of $105.27 and a 12-month high of $139.06. The company has a market cap of $187.66 billion, a price-to-earnings ratio of 29.03, a price-to-earnings-growth ratio of 1.72 and a beta of 0.74. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock’s 50 day simple moving average is $114.58 and its 200 day simple moving average is $123.80.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same period in the prior year, the business earned $1.34 EPS. The firm’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Leerink Partners decreased their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Citigroup reduced their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Piper Sandler decreased their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Raymond James Financial lowered their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $136.16.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock worth $353,097 over the last 90 days. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.